Geneva, Nov. 3 -- International Clinical Trials Registry received information related to the study (NCT07220408) titled 'Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis' on Oct. 21.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Telios Pharma, Inc.
Condition:
Allergic Conjunctivitis
Intervention:
Drug: TL-925
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 2025
Target Sample Size: 60
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/N...